Strategy

trg-entree-estTransgene operates under a business model based around its expertise and fully integrated capabilities for the discovery and development of novel viral vector-based targeted immunotherapeutics.

Therapeutic partnering strategy: out-licensing to major pharmaceutical partners

Transgene uses its in-house discovery and development resources to discover, evaluate pre-clinically, and then test in human clinical studies a wide range of novel immunotherapeutics. The company focuses on two therapeutic areas – oncology and infectious diseases.

Transgene may seek to partner these programs with leading pharmaceutical partners in the relevant disease areas as they reach key pre-clinical or clinical development milestones.

R&D collaborations and Open Innovation strategy with major pharmaceutical partners and/or specialized biotechs22395305_blog

Transgene has unique expertise in developing targeted immunotherapeutics utilizing a wide range of viral vectors. This expertise, combined with a comprehensive infrastructure for drug discovery, development, and manufacturing, including formulation and process development, makes a powerful drug creation platform.

Transgene is therefore ideally placed to become the immunotherapeutic partner of choice for pharmaceutical companies looking to enter the field of viral vector-based immunotherapeutics or to bolster their internal efforts in this area.

Transgene’s model for R&D collaborations is extremely flexible to meet its partners’ needs, including:

– Utilization of a variety of viral vector platforms, including MVA, oncolytic vaccinia and adenovirus platforms.

– R&D in the areas of infectious disease and oncology.

– Collaborations based on different R&D concepts.

These range from de novo therapeutic discovery and development of immunotherapeutics for use as a standalone therapy or in combination with other treatments, to vectorization of a partner’s therapeutic molecule within a single virus-based therapeutic to provide a) more effective targeting, b) production of the partner’s therapeutic “in-situ” and c) potent “single administration” polyvalent therapies.

– Ability to take programs to different stages of development

Transgene’s capabilities run from discovery through clinical proof-of-concept, including manufacturing.

Meetings

BioEurope Spring
Amsterdam, Netherlands
March 12-14, 2018

International Oncolytic Virus Conference
Oxford, United Kingdom
April 9-12, 2018

The International Liver Congress™
European Association for the Study of the Liver (EASL)
Paris, France
April 10-15, 2018

American Association for Cancer Research (AACR) Annual Meeting
Chicago, IL USA
April 14-18, 2018

PEGS 2018
Boston, MA USA
April 30 – May 4, 2018

International Poxvirus Asfarvirus & Iridovirus Meeting
Taipei, Taiwan
May 26-31, 2018

American Society of Clinical Oncology (ASCO) Annual Meeting
Chicago, IL USA
June 1-5, 2018

European Society for Medical Oncology (ESMO) Congress
Munich, Germany
October 19-23, 2018

Society for Immunotherapy of Cancer (SITC) Annual Meeting
Washington DC, USA
November 7-11, 2018

AASLD, The Liver Meeting®
San Francisco, CA USA
November 9-13, 2018